ARTICLE | Clinical News
Aflibercept ophthalmic solution: Phase III started
May 9, 2011 7:00 AM UTC
Last month, Bayer's Bayer HealthCare unit began the double-blind, international Phase III VIVID-DME trial to compare 2 mg intravitreal VEGF Trap-eye given monthly or every 2 months following a monthly...